RecruitingNCT05028062
Extended-release naltrexone or placebo for people with alcohol use disorder
About this title
Read the official source — NCT05028062Medication studyAges 18–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- PhiladelphiaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 7, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- University of Pennsylvania
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05028062
- Official title
Show the full official title
Testing the Reward-Drinker Hypothesis of Naltrexone Using an Extended-Release Formulation
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Philadelphia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Pennsylvania, a university.
Does this study involve medication?
Yes. The study involves medication, including XR-NTX 380 mg, intramuscular injection and Placebo intramuscular injection.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
